Law firm Bleichmar Fonti & Auld LLP announced on November 10, 2026 that a securities class action lawsuit has been filed against The Chemours Company and certain of its senior executives, alleging misrepresentation of demand for its Opteon refrigeration products.

Key Highlights

  • Stock drop: Chemours shares fell $3.34 per share, or 18.63%, on August 5, 2026, from a closing price of $17.93 to $14.59.
  • Case caption: The lawsuit is captioned Darcy v. The Chemours Company, No. 26-cv-1299, pending in the U.S. District Court for the District of Delaware.
  • Lead plaintiff deadline: Investors have until December 7, 2026 to ask the court to be appointed lead plaintiff.
  • Guidance cut: Chemours reduced its 2026 adjusted EBITDA guidance by approximately 11%, to $775M-$825M from $800M-$900M, according to the complaint.
  • Alleged disclosure failure: The complaint alleges Chemours failed to disclose that customers were already oversupplied with Opteon products, resulting in an "oversupplied channel heading into 2026."
  • Legal claims: The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Allegations Against Chemours and Its Opteon Segment

According to the announcement by Bleichmar Fonti & Auld LLP, the class action targets The Chemours Company (NYSE:CC) and certain senior executives over statements related to Opteon, the company's line of refrigeration chemicals marketed as having a reduced ozone-depletion footprint. The complaint alleges that Chemours represented that continued adoption of the U.S. AIM Act -- legislation enacted in late 2020 directing the EPA to oversee the transition to alternative refrigerants -- was driving sustained growth for Opteon products. Specifically, the complaint references Chemours's statements that "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the AIM Act.

The complaint further alleges that Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M-$900M, driven by "higher . . . demand" in its Opteon segment. As alleged in the complaint, Chemours failed to disclose that customers had already become oversupplied with Opteon products as a result of the AIM Act transition, leaving an "oversupplied channel heading into 2026."

On August 4, 2026, Chemours announced Q2 2026 financial results showing an approximately 1% year-over-year decrease in net sales, and disclosed that customers had "built additional inventory" of Opteon products the prior year and that aftermarket channels had been filled. The company simultaneously cut its 2026 adjusted EBITDA guidance to $775M-$825M. The following day, August 5, 2026, the stock closed at $14.59 per share, down 18.63% from the prior session's close of $17.93.

What Was Disclosed

Bleichmar Fonti & Auld LLP announced a securities class action against The Chemours Company and certain executives, alleging fraud related to Opteon demand disclosures. The case is pending in the District of Delaware, with a lead plaintiff deadline of December 7, 2026.